NAPOLI-3: An open-label, randomized, phase III study of first-line liposomal irinotecan+5-fluorouracil/leucovorin plus oxaliplatin versus nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma.

被引：0

作者：

Wainberg, Zev A.

Bekaii-Saab, Tanios S.

Hubner, Richard

Macarulla, Teresa

Paulson, Andrew Scott

Van Cutsem, Eric

Maxwell, Fiona

Moore, Yan

Wang, Haofei Tiffany

Zhang, Bin

O'Reilly, Eileen Mary

机构：

[1] Univ Calif Los Angeles, Med Ctr, Los Angeles, CA 90024 USA

[2] Mayo Clin, Scottsdale, AZ USA

[3] Christie NHS Fdn Trust, Manchester, Lancs, England

[4] Vall dHebron Univ Hosp, Barcelona, Spain

[5] Vall dHebron Inst Oncol, Barcelona, Spain

[6] Texas Oncol US Oncol Network, Dallas, TX USA

[7] Univ Leuven, Leuven, Belgium

[8] Ipsen, Abingdon, Oxon, England

[9] Ipsen Biosci, Boston, MA USA

[10] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4661

引用

页数：2